top of page
Search

UK MHRA Guidance: GLP-1 Medicines for Weight Loss and Diabetes: What You Need to Know

In recent years, GLP-1 receptor agonists have gained widespread attention for their dual role in type 2 diabetes management and weight loss. While these medicines offer promising health benefits, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Department of Health and Social Care (DHSC) have issued a public guidance to ensure their safe, ethical, and informed use.


ree

What Are GLP-1 Medicines?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medicines that help:

  • Lower blood sugar levels by increasing insulin secretion.

  • Suppress appetite, making them effective for weight management.

  • Slow gastric emptying contributes to a feeling of fullness.

Commonly prescribed GLP-1 drugs include:

  • Semaglutide (marketed as Ozempic and Wegovy)

  • Liraglutide (Saxenda, Victoza)

  • Dulaglutide (Trulicity)

Originally developed for type 2 diabetes, these drugs are now increasingly being used for weight loss, particularly in patients with obesity or related metabolic conditions. These medicines are often referred to in the media as “weight loss injections” or “skinny jabs.” However, it’s important to note that not all GLP-1 medicines are authorized for weight loss—many are specifically indicated for diabetes management.


The UK government has issued updated guidance to ensure the safe use of GLP-1 medicines. Key recommendations include:

  • Pregnancy and Contraception: Patients should avoid pregnancy while using GLP-1 medicines, as their safety during pregnancy has not been established. Effective contraception is advised for those of childbearing potential.

  • Side Effects: Common side effects include nausea, vomiting, and diarrhea. Patients should be aware of these and report any severe or persistent symptoms to their healthcare provider.

  • Surgery Considerations: Special guidelines exist for patients undergoing surgery while on GLP-1 medicines, as these drugs can affect digestive function.

  • Proper Syringe Disposal: Used syringes and pens should be disposed of safely, following local guidelines, to prevent injury and environmental harm.

  • Not for Quick Weight Loss: GLP-1 medicines are not intended for rapid or cosmetic weight loss. The MHRA has not assessed these medicines for non-medical, quick-fix use.


Recent updates to the guidance emphasize:

  • The importance of avoiding pregnancy and using contraception during treatment.

  • Awareness of potential side effects and the need for medical advice if they occur.

  • Proper disposal of medical devices used for injection.

  • Clear communication that GLP-1 medicines are not a shortcut for weight loss and should not be used without medical supervision.

For more information on these safety measures and updates, please refer to the official guidance here: "GLP-1 medicines for weight loss and diabetes: what you need to know".



Comments

I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page